Federal Agency · Defense Health Agency Contracting Activity - DHACA
DoW Toxic Exposures Translational Research Award
Last updated: September 6, 2026
Posted May 21, 2026
Funding
Funding amount not specified
Closes
November 19, 2026
NAICS
541715
Summary: The intent of the fiscal year 2026 (FY26) Toxic Exposures Research Program (TERP) Translational Research Award (TRA) is to support translational research that will accelerate the movement of promising ideas in military-related toxic exposure research into clinical applications, including health care products, interventions, technologies and/or clinical practice guidelines. Translational research may be defined as an integration of basic science and clinical observations. New Approach Methodologies may also be used. Applications should provide evidence for the reciprocal transfer of information between basic and clinical science, or vice versa, in developing and implementing the research plan. Distinctive Features: To encourage applications that include meaningful and productive collaborations, the FY26 TERP TRA includes a Partnering Principal Investigator Option (PPIO). One Principal Investigator (PI) is identified as the initiating PI, and an additional PI may be identified as a Partnering PI. If recommended for funding, each PI will be named on separate awards. The intent is to support interdisciplinary partnerships, such as those between clinicians and research scientists, that will accelerate the movement of promising ideas into clinical applications. Partnering should significantly advance the research beyond what would be possible through individual efforts. https://cdmrp.health.mil/pubs/press/2026/terppreann
Eligibility
- Funded by Army
Award details
Applications close on November 19, 2026 (73 days remaining).
Categories
Not categorized
Sign up at GrantRegister to see if this grant matches your organization.
Match my organization →View application on Grants.gov →·Source: Grants.gov·Last seen Sep 6, 2026
Similar grants
- Applied Drug Policy Research ExperiencesOffice of National Drug Control Policy · closes September 6, 2026
- Building Lasting U.S.-Chad Partnerships to Promote American ExcellenceU.S. Mission to Chad · closes September 6, 2026
- Alcohol Health Services Research (R01 Clinical Trial Optional)National Institutes of Health · closes September 7, 2026
- Substance Use/Substance Use Disorder Dissertation Research Award (R36 Clinical Trials Not Allowed)National Institutes of Health · closes September 7, 2026
- Social disconnection and Suicide Risk in Late Life (R01 Clinical Trial Optional)National Institutes of Health · closes September 7, 2026
- Schizophrenia and related disorders during mid- to late-life (R01 Clinical Trial Optional)National Institutes of Health · closes September 7, 2026
- Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed)National Institutes of Health · closes September 7, 2026
- National Centers for Biomedical Imaging and Bioengineering (NCBIB) (P41 Clinical Trials Optional)National Institutes of Health · closes September 7, 2026
